MOTS-c alternatives.

7 compounds compared to MOTS-c, ranked by published evidence tier and regulatory status, not by what's marketed hardest.

Why people look for an alternative

MOTS-c is one of the small family of mitochondrial-derived peptides, encoded inside the mitochondrial 12S rRNA region rather than the nuclear genome, and first described around 2015. That novelty is most of its appeal and also the problem: it is not approved by the FDA or any major regulator for any indication, is not a recognized dietary supplement, and has no registered human therapeutic trials. So people searching for alternatives are usually looking for the same metabolic-signaling idea with clinical data behind it. Within this family, humanin has the same gap; SS-31 is the one mitochondria-targeted peptide that reached approval, for a rare genetic condition rather than metabolic health.

What you're comparing against
MOTS-c
F tier · 30/100Research / preclinical

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015.

Ranked by evidence · strongest first
  1. 01
    SS-31
    C tierIn human trials
    elamipretide

    Acts through the mitochondrial peptide signalling pathway, like MOTS-c. In human trials.

  2. 02
    Humanin
    F tierResearch / preclinical

    Acts through the mitochondrial peptide signalling pathway, like MOTS-c. Research / preclinical.

  3. 03
    Glutathione
    D tierResearch / preclinical
    GSH · reduced glutathione

    Same category: longevity. Research / preclinical.

  4. 04
    Epitalon
    F tierResearch / preclinical

    Same category: longevity. Research / preclinical.

  5. 05
    5-Amino-1MQ
    F tierResearch / preclinical

    Same category: longevity. Research / preclinical.

  6. 06
    FOXO4-DRI
    F tierResearch / preclinical

    Same category: longevity. Research / preclinical.

  7. 07
    Vilon
    F tierResearch / preclinical
    Lys-Glu dipeptide

    Same category: longevity. Research / preclinical.

How this list is built

An “alternative” here means a compound that shares MOTS-c's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.

Comparing options with your provider?

PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page
Compounds